Valeo Pharma says Redesca now has public reimbursement coverage in nine Canadian provinces

Valeo Pharma Inc reported it had now secured public reimbursement coverage for its anticoagulant drugs Redesca and Redesca HP in nine Canadian provinces after striking a product listing agreement (PLA) for Quebec.

It comes as the drugs are also currently listed for reimbursement under private payer health plans, which currently represent more than 90% of privately covered lives across Canada.

The company’s Redesca is a low molecular weight heparin biosimilar, used mainly to treat deep vein thrombosis and pulmonary embolism. Redesca has over eight years of proven in-market safety internationally, and more than 150 million patient days treated in Europe alone.

“Biosimilars usage is rapidly growing throughout Canada and contributing to significant savings to provincial healthcare plans. With more than 8 years of proven in-market safety data internationally and a robust supply chain ensuring product availability, we expect Redesca to continue playing a major role in the achievement of our growth objectives,” said Frederic Fasano, Valeo’s chief operating officer.

READ: Valeo Pharma obtains public reimbursement for innovative asthma therapies Enerzair and Atectura

Valeo Pharma is dedicated to the commercialization of innovative prescription products in Canada with a focus on respirology, neurodegenerative diseases, oncology and other specialty products.

Headquartered in Kirkland, Quebec, is has the complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.

Contact the author at [email protected]

Story by ProactiveInvestors